important things We know everyone. are going Good of now. Ioana. lots you, afternoon, Thank on right there
some call. on clinical join our XXXX able you full followed update who very describe to programs. XXXX of we those conference much each going today our plans for of XXXX So by brief first our for then to a review us activities year are appreciate I'm of our
us by on for areas unmet XXXX early the was because therapy path be in saying cell year need. in year stage an best So that incredibly focusing important off the clinical by high would the we I'll with start opportunities decided success to
meant being far a create focus potential to we current on our extraordinary to company, able and would opportunity offer shareholders compelling more intensely injury of many in and therapy class streamlined product cell establish a focused resources cord and biotech a our using knew both therapeutics. new AMD, our development be Following needed cancer. to that by more future priorities to driven historic and of new by spinal that we the that path change We activities, dry of
of we based was branch successful to Our restore our activity path which disease. overall new from could on a cell strong driving is which cells set injury the on a forward foundation loss, objective for this therapy XXXX intact transplanting company. ultimately create firmly to And or therefore now is into become medicine, body
three the areas. therapies in to away and cell to effort initiatives embrace some historic our development the of year-long Our of significant make us opportunities with associated required from move clinical fully changes
had additional our to assets. and development GMP product stage capacity. let cord we two the where This expanded trained we First, by injury facility diversified manufacturing acquiring move Israel, our in pipeline program us available also staff spinal for and clinical
to which on mission, senior our or hub new the on beyond. our cut value Diego. of their reflect to for but focused the goals our name and budget to the in changing had activities half, through company's nearly Along executives goals. move of were of XXXX million our not stated XXXX efficient have third, trials ensured biotech headcount four product inception. value opportunities. which our innovative the we together, from an team, steps priorities approaching that a strong created $XX headquarters for to communicate also All right our being revamped our record million talent six we've our we an reduced to had track conducting And way, unrelated anticipated of sold organization meet XXXX only This clearly highest human near-term stopped with these pool management our to we since and diminished updated and San and or $XX off mission pipeline, our able significant place milestones. deliver net Second, in our core even We advancing demonstrated and operating by
to that OncoCyte instead our I'll and origins able equity to relying to Lineage. their conduct which ability at to raise our add we offerings were cash companies organizational AgeX having on additional without from in transformation this complete had investments
deeply approximately represent of and investments set I'm productive we to out team these to setting us yesterday, year to ago. can of all we for $XX million one be and $XX securities for paid And of and will which up their XXXX. incoming operations work this we to exciting August. expect marketable note We And an everything for year do achieved well our As hard appreciative use us receivable, of XXXX. which expect our this into we fund million almost
Looking ahead, intend capitalize and to progress our continue momentum. our we on
trial OpRegen that enrollment ongoing Our in is late for discussions. will designs primary collect data guide and the and goal stage dry our AMD clinical of XXXX partnership for our complete to trial
enhancements launch its our stage its into and to a broad enhance manufacturing continue patient of expect process, next advance we greatly clinical clinical for introducing We by which late-stage of will the for OPCX ease access. trial, program commercial deployment preparedness surgeons will also to ultimately the development the its work use into
development are have to our non-small-cell generated one phase trial. with the significantly of acquire in Cancer VACX we option our in exercise data patients whether increased Research ongoing trial partner that cancer. the interactions with UK lung And we to Lastly, our on evaluating
raise allows which our markets access which And next us make our But even it Brandi particular summaries, section, changes impact explained I well before difficult wondering no some to program has of I fund for the into I know capital. erratic may companies and capital business. Now her the our plan. we equity explain be year to operating the to provide or many to in will as extremely as been coronavirus whether further can with note, have could you operations have
we have So assess accordingly. plenty of and markets to act situation the financial time the
As that number of of place. today, rising been put growing the in we've are by the cases number not impacted of precautions or being
the situation because However, know it quickly. is we we monitor do changing closely
reason, have widespread. become already For some quarantine simple have procedures restrictions and adopted and this plans more we travel considered as mitigation
clean acted to we example, room reagents early For procure equipment. and key
be navigate as for any things with and adjust disruptions. But our and disruptions. chain to most the intelligently virus related we and needed. watch of impact monitor continue or enrollment like financial Overall, patient we'll our position we Looking will likely to the on ahead, ability and to supply comfortable feel operational course
expect the most OpRegen will year updates therapies. there complete, the review no to and an this to see each that development for program I'm XXXX. begin financials to dry next FDA I the Brandi fourth AMD year. approved We which are data With of and sufferers OpRegen, provide throughout for value on company to quarter significant driver we inviting treat before our the year our millions candidate as going full but clinical update for review product provide for
to in May. continue meeting program same originally learned that morning been to data so was Our you for look early scheduled provide to that ARVO the we on timeframe the OpRegen We update can cancelled OpRegen this still has an that update next but event. on plan meeting the in forward
I'm best the explain heard to and of briefly production me to through outcomes. the have points the possibly shot what You've say positive we walk each combine at these delivery order cells, the clinical in want best I that best mean. to exactly to going best
and with unlimited self will which of our material. approved ago these simply from we best First, of cells. and established normal is made because has continuously pluripotent cellular grow line no an line extensive need and years pluripotent more manufacture us The use modifications. what division cells NIH through a which have amount we cell We cells characterization XX double we cells believe to provide cell the undergone was starting genetic are retina have than them we we thaw we an number if more essentially and bio renewing,
starting We of millions have we can population multiple the an locations material cells produce of almost these entirely pure from and banked RPE away in cells. active functionally
rigorous meet our assays purity identity have use which potency in for to go clinical criteria We exceed they regularly trials. and ensure and our cells testing XX% through sterility,
I best we the cell Second, have production believe capabilities.
and with kind of entirely we because country make terms in Obviously, bioreactor a this reactor. scale a up. cells staff clinical our trained increase production therapeutic has in point now how XXX,XXX potential and associated production is fortunately impressive millions from alone, than commercial dose patients plans highly generate the Israel of some from this we we reduce can we're closed which single can can savings of XX-person and milk at because of an to one manufacturing thousands gallon have single we jug costs, can provides further process risks a but scale manufacturing doses reactors in cells, for running smaller improved almost five with run system, RPE billion we a only our multiple Our
RPE already have to need away frozen clinical thousands even ready cells larger to because isn't of work we of studies year something begin. doses this OpRegen However, this we for on
right Our delivery into the We the the which of strategic times. exclusive to Gyroscope delivery license described advantages option Therapeutics many their I've FDA-cleared system we potential dry to a device deliver AMD. the subretinal and third this entered having cells of advantage use under for is with treatment system. best have agreement
lead procedure that will clinical safer thus dose we less I it will So and reiterate a variability. control believe simply with better to
use went new the best with formulation. the that And individual device letters far SDS complications. encouraging dosed of thaw-and-inject was in our both baseline it's fact, two That patient after months and so to treatment. individual procedures that's serious on who date of reported above device SDS using no and responding We've surgeries in XX the six gained the well our
to for So performance device company Again the with we're early can and more is use other cells patients. the no the this exclusive SDS we're AMD. on OpRegen device to so Lineage of deliver forward treating delighted SDS dry to the looking device option with
thaw-and-inject this challenging before is other prepare the which many cells every formulation cases facility to proprietary way. operationally to injection economically the successfully therapy with new also SDS cells introduced equipped in some and cell necessary for not handle With in device. approaches, since our it's use, We day is
Our cells than attractive commercially process. minutes a a vial RPE which permits the preparation formulation thaw-and-inject dosing, and just user-friendly to complicated our a before dose and more few is of surgeon thaw much time-consuming
cells, best clinical And best is and generated that mean encouraged we're the best date, we when in by production approach. delivery. evidence say our of the So what we we've combining we're to support
who We we in of preliminary structural notably evidence cohort of patient patients retina disease more of also have population. our who retina as most improved characteristics have and thickening advanced less or accurately anatomical in layer And represent vision, evidence such drusen our intended or the preliminary have improvements four reduction.
of this in highly it reproduce and can encouraging more confidence if become the it All compelling but significantly our increase to additional observations. is patients in able we're
treated strategies of this the present we discussions. this At the So to us and help this expect sites our and OpRegen to patients. update identify well to new entirely next At for on two with trial additional data opening more trying early as in and quickly as reflection reason, remove be permission to These data as with stagger will is time, And US data recently time, this as consistent primary previously inform new and will enroll obtaining clinical, goal partnership a is regulatory study. our to eligible year reach goal this patients clinical that anticipate us points them can. patients data May. the from on ongoing from we we in treated and enrollment
next such into size the study partnership. whether design strategic as the and We have to for decisions important enter and its ahead
data forthcoming they share So we our become decisions the as and be collecting will and interpreting available.
and spinal to OPCX the with cord next tech GMP to injury. acquired We transferring we facility. fall program responsibilities in Moving successfully for XXXX our Lineage and moved manufacturing had program early to all operational our by this control
to and manufacturing data, clinical has trial. generated not positive process this clinical program ready we late-stage promising was While the acquired support a extremely
which increasing Attributes we working characteristics went So scale-up. work better we of product. to introduce immediately and the to on control things like been consistency, production reproducibility have to process the include for
successfully OpRegen program. all These are achieved we things with have our already
to also OPCX. these we similar successful time commercial in are these that features distant And will considerations. optimistic introducing we're So be not
the have we're near-term Some will benefits. enhancements of working on valuable
a trauma advance had OPCX, in to one cells staff. prior clinical one and acceptable in in be to processed the buffer of trial day center thawed were technical shipped on-site the and clinically the As example and resuspended by
the a the something I number ago explained which do is can even sites not a context moment As of this can puts in that constraint clinical facility of OpRegen, you on every open.
might not study it's or study not phase one an pilot larger for practical as but a trials. Now simply be impediment for a
we on with of developing won't will be we are trials. successful working for the reduces need to we're think new be so to dose for we're to centers the to using won't able the it we which formulation we successful reminder, more So thaw-and-inject And for same be this and If doing only sites we the OPCX successful in limited open OpRegen surgeon preparation a in equally means facility wait creating with formulation so for and the we a formulation, sooner finish same capabilities. a were will processed OPCX. cells be thaw-and-inject enrolling cost this new as trials those staff and
might means I cord OpRegen OPCX. competition gain obtain delivery treatment and optimal overall this also with Gyroscope experience anything OPCX. now with long-term for and in to by our looking to our to spinal we device assemble our you don't novel an for to delivery to share discussions don't management, but device We ways and ourselves a device delivery every exclusive success. an today, care reflects copy make have it just and proprietary access at specific a we're the We to some parts best We And available combining outmaneuver which for commitment of total wanted to announce very and and initiative we intend wise We're made the new exploring to have asset a SDS exclusive just connection cells, option position the regimen. begun we because provide proposition, piece cells. analyzing production the component of decision
We've made quarter. expect updates some begin share these OPCX progress you we and on that specific will to enhancements next can excellent
load tumor specific comprised with patients a an spinal is instruct your stage retina X lines dendritic VACX. cells UK This out and In educating eliminate vaccine mature is cord cells. Our cells for cancer system the cell clinical body's VACX from cells. third this by oncology pluripotent way, program managed VACX partner system cells. your a which our which in to dendritic immune is just seek to clinical lung Cancer off-the-shelf manufacture and being cancer we attack Phase well-established UK. antigen is currently of is our We our and called cancerous by like booster these intended like immuno a Research marker non-small-cell CR trial program t-cells acts destroy of with cancer. immune This conducting to
are additional acquired it have to when program. slow explain extremely was program patients provided say And on now. CR I about that last update program the trial. we VACX an moving dosed but this to we I'm for year, better last since this really pleased this responsible I'd share like on much solely more is Progress UK must that been but things
permitted its our the of that data most do the So we can also with it's interest we and collaboration. discuss VACX to obtained option although to we to from so. to the data us of we're the if pay regain does get I only they are shared part which will exercise for which program time release time timing generating, control say in don't cannot the for the from control have we data, and not
will factors that it and without However, many there go would not are evidence. supporting be into done and decision which clear compelling
to the particular, and be area value and compelling strategies antigen. evidence patients option our exercise this the reason a have to exercising efforts exciting research they a want to we consider of for prepare candidate. cancer to developed development begun see there intended in effort a would our of the we In VACX will potentially the meantime immune we of this that we the response product might promising have do possibility which If the option, for some expand small in of to believe
therapy are have our three activities we currently, want although company main the Now to a for clinical of programs the cell mention. other important that I drivers number ongoing
the allows and is in the First, have aesthetics advisory process or territories to and European have not present aesthetics it develop to engaged That the evidence and product our partner to a facial operations competitive launch the granted in or ongoing and the is do we sold year an of because both regulatory recognized. last and This to But was been leading which approval partnership EU the of some capabilities is CE firm we the firms. fragmented. other to EU, where aesthetic CE further Lineage a strong European market. in mark have mark either clinical is be team opportunity we the of Renevia identify further able Renevia the
will continue with process provide when we shareholders see becomes options and available. additional So our this are and our information it what
licensing agreements our Second, effort as property late extensive part estate. to intellectual last separate we monetize of with entered companies our three year into
us positions to do we as entering to And an well money agreements, create by time, We seek in-house by to also the high-value better there's into at opportunities we to new prosecution attorney in will IP recently opportunity save reducing IP where as hired license in costs. so. believe an additional seek our which to same will patent allow take money out areas
added manufacturing to the our with all of programs. of layers associated patents granted were types recently our which protection three we of example, further For cell
stem differentiated additional generating iPSCs, for of potential induced describing or an received our the the alternate use pluripotent application cells patent rights also option further of work. broadening cells, We
grants Institutes as We entities year for work. papers other the and dilutive abstracts the to last National more intend Health. Regenerative awarded or than present as support work Authority publish Israel Third, to describing from Institute we of such and seek the to our these well were and from non or three CERN California US for Innovation the our continue Medicine as
With and over our to hand this for will review year. things now financials that plans to discuss additional some Brandi I
